PYXS
NASDAQ
$2.25
Pyxis Oncology Inc (PYXS)
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6.75 (+200.00%)
Market Cap
$153M
Free Cash Flow Yield
-43.87%
Beta (5Y)
1.37
Price Chart
Valuation
Market Cap$153M
P/S10.69
P/B4.65
Profitability
Total Revenue (TTM)$13M
Gross Profit (TTM)$11M
EBITDA-$81M
Operating Margin-600%
EPS-$1.31
Financial Health
Free Cash Flow Yield-43.87%
Growth & Risk
Beta (5Y)1.37
Sharpe Ratio1.15